Progress for Boehringer/Lilly re diabetes tablet
A bit of good news might be coming soon for the 425 million people worldwide with type 2 diabetes who have to take multiple medicines...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
A bit of good news might be coming soon for the 425 million people worldwide with type 2 diabetes who have to take multiple medicines...
From the Rome Smith & Lutz team: The Connecticut General Assembly adjourned sine die the 2019 regular legislative session. Governor Lamont will address the joint...
Vanessa Research has been granted regulatory approval by the Turkish Ministry of Health to conduct a Phase II Clinical Trial for Shylicine®, an investigational oral...
SpringWorks Therapeutics reports that the FDA has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment...
Four New Haven-area companies exhibiting at Bio 2019, one the world’s largest forums for the biotech sector. More than 16,000 attendees are taking part in...
Intensity Therapeutics reports positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American...
Bayer and Arvinas report an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and...
Stamford-headquartered Sema4 has introduced a line of genomic testing services and digital tools designed to aid oncologists treating cancer patients from the risk assessment to...
Ann Nyberg of WTNH News 8 recently interviewed Dawn Hocevar, President & CEO of BioCT. Highlights: * The bioscience industry in Connecticut is making a...
Thetis Pharmaceuticals reports preclinical data supporting the potential of its lead candidate, TP-317, in inflammatory bowel disease (IBD). TP-317 is a novel salt of Resolvin...